2.50
Hdl Handle:
http://hdl.handle.net/2336/15871
Title:
Post-induction residual disease in translocation t(12;21)-positive childhood ALL
Authors:
Seyfarth, Jeanette; Madsen, Hans O; Nyvold, Charlotte; Ryder, Lars P; Clausen, Niels; Jonmundsson, Gudmundur K; Wesenberg, Finn; Schmiegelow, Kjeld
Citation:
Med. Pediatr. Oncol. 2003, 40(2):82-7
Issue Date:
1-Feb-2003
Abstract:
BACKGROUND: t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25% of B-lineage ALL cases and has been claimed to carry a good prognosis. PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis. RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03%, P = 0.12). CONCLUSIONS: Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxorubicin given during induction therapy.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1002/mpo.10217

Full metadata record

DC FieldValue Language
dc.contributor.authorSeyfarth, Jeanette-
dc.contributor.authorMadsen, Hans O-
dc.contributor.authorNyvold, Charlotte-
dc.contributor.authorRyder, Lars P-
dc.contributor.authorClausen, Niels-
dc.contributor.authorJonmundsson, Gudmundur K-
dc.contributor.authorWesenberg, Finn-
dc.contributor.authorSchmiegelow, Kjeld-
dc.date.accessioned2008-01-09T14:29:04Z-
dc.date.available2008-01-09T14:29:04Z-
dc.date.issued2003-02-01-
dc.date.submitted2007-01-09-
dc.identifier.citationMed. Pediatr. Oncol. 2003, 40(2):82-7en
dc.identifier.issn0098-1532-
dc.identifier.pmid12461790-
dc.identifier.doi10.1002/mpo.10217-
dc.identifier.urihttp://hdl.handle.net/2336/15871-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractBACKGROUND: t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in approximately 25% of B-lineage ALL cases and has been claimed to carry a good prognosis. PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis. RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03%, P = 0.12). CONCLUSIONS: Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxorubicin given during induction therapy.en
dc.language.isoenen
dc.publisherWiley-Lissen
dc.relation.urlhttp://dx.doi.org/10.1002/mpo.10217en
dc.subject.meshAdolescenten
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshChromosomes, Human, Pair 12en
dc.subject.meshChromosomes, Human, Pair 21en
dc.subject.meshCore Binding Factor Alpha 2 Subuniten
dc.subject.meshDNA Primersen
dc.subject.meshDoxorubicinen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunophenotypingen
dc.subject.meshInfanten
dc.subject.meshMaleen
dc.subject.meshMethotrexateen
dc.subject.meshNeoplasm, Residualen
dc.subject.meshOncogene Proteins, Fusionen
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphomaen
dc.subject.meshPrednisoloneen
dc.subject.meshRNA, Messengeren
dc.subject.meshRNA, Neoplasmen
dc.subject.meshRemission Inductionen
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen
dc.subject.meshTranslocation, Geneticen
dc.subject.meshVincristineen
dc.titlePost-induction residual disease in translocation t(12;21)-positive childhood ALLen
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark.en
dc.identifier.journalMedical and pediatric oncologyen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.